Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.625 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
6.25 7.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.01 -3.70 -0.76 30
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 6.625 GBX

Collagen Solutions (COS) Latest News

More Collagen Solutions News
Collagen Solutions Investors    Collagen Solutions Takeover Rumours

Collagen Solutions (COS) Discussions and Chat

Collagen Solutions (COS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Collagen Solutions trades in real-time

Collagen Solutions (COS) Top Chat Posts

DateSubject
23/7/2021
09:20
Collagen Solutions Daily Update: Collagen Solutions Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker COS. The last closing price for Collagen Solutions was 6.63p.
Collagen Solutions Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 6.63p while the 1 year low share price is currently 2.50p.
There are currently 446,878,910 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Collagen Solutions Plc is £29,605,727.79.
12/11/2020
14:05
moontheloon: Still positive about Polx tutte? I find it hard to get positive at mo.. When been immersed in cos for years.. But seems like a good product...
20/10/2020
15:08
40 fathoms: Moon, No there is no possibility of a higher offer price, holding out for longer will just delay when you get paid your 6.5p per share. In terms of when you get paid if you accept the offer, they have 14 days to pay you from the date of your acceptance.
09/10/2020
11:13
nxc: 40Fathoms - Thank you for your kind words. As you pre-supposed I do not agree with your assessment of the Board - as individuals they are of the highest integrity and I would trust each of them with my house keys. You have clearly highlighted an issue in how you and others have been communicated to and in that regard perception is reality - the perceived lack of communication has generated a level of dis-trust which is difficult to shake-off. As I am no longer at the Board Table I cannot offer you any insights - it may be down to the Takeover Code and advisers interpretation of the Code. Personally I would not have gone public on the sale process but perhaps their hands were tied in that regard. I understand the angst around Chondro - perhaps I am jaded by the experience but it began to have the look of a mirage in the desert - I felt at the start that there was a clear route map to success - perhaps I and the rest of the Board were naive in failing to understand fully the shifting sands of regulatory compliance/approval - some of the output from the regulatory agencies are in my view beyond comprehension and are reflective of a deeper seated issue that exists in Government ( Uk/EU/USA/China etc)with regard to new product approvals where ultimately the net cost of compliance both slows innovation but also increases the cost to such a high level that patients and payors are not well served. I think in conclusion Rosen's have paid a fair price and the alternative of a significant fundraising at 1p to 2p in my view did not serve my interests.
09/10/2020
08:45
40 fathoms: NXC I have to say I agree with both Moon and WTT with respect to the COS board. I think their performance has been woeful, almost to the point of incompetence in their handling of matters this year. Clearly they are people you know well and as a man of good standing I would not expect you to do anything other than disagree with that assessment. However, I am absolutely certain if your health had allowed you to remain as chairman we would today have a clear understanding (for better or worse) where things stood with Chondro, and if indeed 6.5p is the right price for the business why 6.5p is the right price and an understanding of how the board came to that decision. As of today we have none of these understandings. When you stepped down, the board lost all of its entrepreneurial spirit and the understanding of how to protect and treat the small investor. To my mind only Mr. Gillies comes across as being suitable for the board of a listed company. I hope your health situation is stable and I wish you well.
06/10/2020
12:00
40 fathoms: If they get to 90% it won't be because of employee options. The outstanding options have vesting conditions attached. For most of the grants it is based on the share price reaching 10p and also achieving sustainable positive cash flows. Those conditions have not been met. Additionally, @ 5.8 million have not met the first exercise date and an additional @ 7.9 million are out of the money.
08/9/2020
16:16
moontheloon: Well if they've bought a considerable amount before offer at 2.5p or pre offer then stand to gain 200-400% but looking at share price for 3 year period. 6.5p per share is pretty dire in my opinion
03/9/2020
16:53
nxc: WTT/Moon - I do understand where you are coming from and value is in the eye of the beholder so I respect your desired outcome. My reasoning behind the downside risk is that if the offeror walks away then the Company will almost certainly require to raise money if only to satisfy the Auditor's on Going Concern where the bar for a clean audit opinion has been raised significantly. My instinct is that a minimum of £4m would be needed and I think in that sense Rosen would have the whip hand in setting the price which would be nearer 1p than 2p. None of the EIS/VCT funds can participate - that leaves myself/Helium and Brett Gordon out of the substantial Shareholders ( apologies to substantial <3% holders but I do not have access to an upto date register)to fund the gap that Rosen cannot fill as they will be limited to an overall shareholding of 29.9%. The dilutory impact is significant and my biggest concern above all others is the impact on Management - they have been through the wringer and contrary to the view that they are self-serving with snouts in a trough they are an incredibly hard working group who I fear are fatigued. Life is not a straight line and the assumptions being made about future value assume most of the dominoes will fall COS's way - experience tells you that is unlikely. COS is vulnerable to the loss of key personnel and we should bear that in mind.
02/9/2020
07:19
w t tutte: I have had a good think about it and I don't want to sell my shares at 6.5p. I think the shares will fall back if the bid is killed but I still feel the long term outlook for the business is strong. Another factor for me is that if the share price is at 2.5p or 6.5p it only has a smallish impact on my savings.
01/9/2020
15:18
nxc: Dreams of higher valuations are just that - to ascribe value without the concomitant significant cash injection necessary to achieve that value needs to be taken into account. If the bid fell away you are looking at a sub 2p share price with a probable 1p fundraise.
21/7/2020
07:10
moontheloon: Should get us going well today and ongoing.. Need news on ce mark and takeover too to add to this, the story of all that potential in this company is beginnning to unfold. But share price rising in meantime bumps up any takeover price. IMHO. Good luck all
Collagen Solutions share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
COS
Collagen S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210723 20:16:44